2 results
Approved WMOCompleted
To determine the efficacy endpoint whether the lack of ATP function will cause more appropriate but unnecessary shock therapy in patients with a S-ICD. Furthermore we will study the complication endpoint whether the S-ICD is superior to the TV-ICD…
Approved WMOCompleted
1. Overall survival (primary efficacy endpoint)2a. Efficacy: progression-free survival (PFS), overall response rate (ORR = CR + PR), and a clincal benefit rate (CBR) will be evaluated as CR + PR + SD for at least 3 months.2b. Safety: adverse events…